Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | NPY2R | P49146 | 1/20 | 0.48 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.48 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.48 |
| ▸ | PPARG | P37231 | 6/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365629 | 0.92 | MMP8 (0.63) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL856250 | 0.91 | MMP8 (0.69) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL15726083 | 0.89 | MMP8 (0.49) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL28250166 | 0.88 | MMP8 (0.66) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| Potassium Ion SCHEMBL7361893 | 0.85 | MMP8 (0.56) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL2050344 | 0.84 | MMP8 (0.53) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL5326604 | 0.84 | MMP8 (0.53) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL7696784 | 0.83 | ESR1 (0.51) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL165382 | 0.82 | MMP8 (0.76) | MMP8ALDH1A1TP53NPY1RNPY2R | |
| SCHEMBL8716748 | 0.82 | TDP1 (0.50) | MMP8TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0180745-A1 | Acylacetate and amidine intermediates for pyrimidone compounds, and their preparation | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1986-05-14 | — | — | EP | claimed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212169-B2 | Benzimidazole derivative and use thereof | HYOGO COLLEGE OF MEDICINE (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | KAGOSHIMA UNIVERSITY (JP) | 2015-01-08 | — | — | US | disclosed |
| WO-2013129674-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | 学校法人兵庫医科大学 (JP) | 2013-09-06 | — | — | WO | disclosed |
| US-5741438-A | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as an effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-21 | — | — | US | disclosed |
| EP-0395390-A1 | Optically active biphenyl derivative, process for preparation thereof, liquid crystal composition containing the same as effective component, and liquid crystal element using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011600-A1 | NOVEL BENZIMIDAZOLE DERIVATIVE AND USE THEREOF | HDAC1, HDAC11, HDAC6 | MMP8 1838/4885ALDH1A1 259/4885TP53 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.